Fact-checked by Grok 2 weeks ago

Cerebral infarction

Cerebral infarction, commonly referred to as an , is a type of that occurs when blood flow to a portion of the is obstructed, depriving cells of essential oxygen and nutrients, which leads to rapid and potential permanent damage. This condition accounts for approximately 87% of all in the United States as of 2022, making it the most prevalent form of cerebrovascular accident. It is typically caused by either thrombotic , where a blood clot forms within a cerebral artery due to , or embolic , where a clot or debris travels from elsewhere in the body, such as the heart, to block a . The underlying pathophysiology involves a critical reduction in cerebral blood flow, below 10-12 mL per 100 grams of per minute, which triggers ischemic penumbra—a salvageable area surrounding the core —before progressing to full if not addressed promptly. Common risk factors include advanced age (over 55), , , smoking, , and , with non-Hispanic Black individuals facing nearly twice the risk of a first compared to other groups. Symptoms manifest suddenly and vary by the affected region but often include unilateral weakness or numbness (), facial droop, speech difficulties ( or ), vision loss, and severe , assessed via tools like the Scale (NIHSS). Diagnosis begins with an urgent clinical evaluation and non-contrast computed (CT) within 20 minutes to rule out hemorrhage, followed by (MRI) with diffusion-weighted imaging (DWI) for confirmation of . Treatment focuses on rapid reperfusion: intravenous with tissue plasminogen activator (tPA, such as ) administered within 4.5 hours of symptom onset, or mechanical using a retriever for large vessel occlusions, ideally within 6 to 24 hours depending on eligibility. Post-acute management includes control (target <180/105 mmHg after tPA), antiplatelet therapy, and to mitigate long-term , which affects up to 795,000 Americans annually as of 2022 and contributes to one in six cardiovascular deaths worldwide as of 2022.

Overview

Definition and epidemiology

Cerebral infarction, also known as ischemic , is defined as the death of or cells attributable to prolonged ischemia, resulting from an interruption in blood supply that leads to in the due to insufficient arterial or venous flow. This condition is distinguished from hemorrhagic , which involves vessel rupture and rather than or reduced . Clinically, it manifests as focal neurological deficits persisting for more than 24 hours, caused by an acute vascular event affecting the , excluding trauma or other non-ischemic origins. Globally, cerebral infarction accounts for the majority of strokes, with approximately 7.8 million incident cases annually, representing about 65% of the 11.9 million total incident reported in 2021. The age-standardized incidence rate stands at 92 per 100,000 population, though absolute numbers have risen by nearly 88% since 1990 due to and aging. Regional variations are stark, with over 83% of incident strokes, including ischemic types, occurring in low- and middle-income countries (LMICs), where and report the highest rates driven by limited preventive care. Demographic trends show an increasing burden among younger adults, with incidence in the 15-39 age group rising globally, particularly in lower sociodemographic index regions, attributed to factors such as and —the leading modifiable risk factor. Mortality from cerebral infarction reaches 3.6 million deaths per year, comprising roughly half of the 7.3 million total stroke-related deaths worldwide, making it the second leading overall. The condition imposes a substantial healthcare burden, contributing 70.4 million disability-adjusted life years (DALYs) lost annually—about 44% of total stroke DALYs and ranking third among non-communicable diseases—with 89% of stroke-related DALYs borne by LMICs due to inadequate access. These figures underscore the escalating global impact, with prevalence affecting 69.9 million individuals living with sequelae.

Historical context

The understanding of cerebral infarction, historically encompassed under the broader term "" or "," evolved from ancient supernatural interpretations to a scientifically grounded recognition of vascular . In ancient times, conditions resembling cerebral infarction were described as sudden calamities, with (circa 460–370 BCE) providing the earliest systematic account in the , terming it "apoplexy" to denote a violent causing loss of sensation, motion, and consciousness, often linked to humoral imbalances rather than divine causes. Earlier and medieval views occasionally attributed such events to divine punishment for sins, reflecting a pre-scientific that interpreted sudden as supernatural retribution, a perspective later supplanted by empirical . During the 17th and 18th centuries, advances in autopsy-based pathology began to reveal the organic basis of apoplexy. Johann Jakob Wepfer, in his 1658 monograph Historiae Apoplecticorum, conducted postmortem examinations that first identified cerebral hemorrhage as a primary cause, challenging humoral theories and linking apoplexy to vascular rupture. Building on this, Giovanni Battista Morgagni's seminal 1761 work De Sedibus et Causis Morborum per Anatomen Indagatis analyzed over 600 cases, distinguishing hemorrhagic from non-hemorrhagic forms of apoplexy and describing brain tissue changes like softening, though the term "ramollissement" for infarction emerged later in the 19th century. The marked a pivotal shift toward cellular and vascular mechanisms, largely through Rudolf Virchow's contributions. In the 1840s, Virchow introduced the term "" to describe tissue necrosis due to , emphasizing and as key processes in his 1846 studies on cerebral . By 1856, he formalized , endothelial injury, and hypercoagulability—as the foundational factors in formation, linking them directly to ischemic events and establishing the vascular of cerebral infarction. The 20th century brought diagnostic revolutions with . The computed tomography (, developed by and first clinically applied in 1971, enabled rapid differentiation of ischemic from hemorrhage, transforming acute evaluation in the 1970s. (MRI), emerging in the 1980s, further refined detection of early ischemic changes. Therapeutically, the 1995 NINDS demonstrated that intravenous tissue plasminogen activator (tPA) administered within 3 hours improved outcomes in acute ischemic , establishing as a standard. The 2015 MR CLEAN then validated endovascular for large-vessel occlusions, showing significant functional recovery benefits. In 2018, trials such as DAWN and DEFUSE 3 extended windows to 24 hours in select patients using perfusion imaging, reflecting ongoing refinements in time-sensitive interventions.

Classification and causes

Types of cerebral infarction

Cerebral infarctions are classified primarily according to the underlying and vascular involvement, enabling targeted diagnostic and therapeutic approaches. The most widely adopted system is the (Trial of Org 10172 in Acute Stroke Treatment) classification, established in 1993, which categorizes ischemic s into five subtypes based on clinical features and diagnostic investigations: (1) large-artery , involving or of major extracranial or intracranial arteries; (2) cardioembolism, resulting from cardiac sources such as ; (3) small-vessel , affecting penetrating arteries and leading to lacunar infarcts; (4) of other determined , encompassing rare causes like arterial or hypercoagulable states; and (5) of undetermined , where no clear cause is identified despite evaluation. This framework, validated in clinical trials, guides secondary prevention strategies by subtype, with large-artery accounting for approximately 20-25% of cases in population-based studies. Classifications also consider vascular territories affected by the infarction, which correlate with specific neurological deficits. Anterior circulation infarcts, primarily in the (MCA) territory, often present with contralateral , , and if the dominant hemisphere is involved, while (ACA) infarcts may cause leg weakness and syndromes. Posterior circulation infarcts, such as those in the (PCA), typically result in defects like homonymous hemianopia, and may extend to involvement with vertigo or cranial nerve palsies. Lacunar infarcts, a subtype of small-vessel , arise from or microatheroma in deep penetrating arteries, producing small (<15 mm) lesions in , , or , and manifesting as pure motor , ataxic hemiparesis, or dysarthria-clumsy hand syndrome in about 25% of ischemic strokes. Special types include watershed infarcts, occurring in border zones between major arterial territories due to hypoperfusion from systemic or carotid , leading to cortical laminar and deficits like proximal arm-leg weakness. Silent cerebral infarcts, detected incidentally on without acute symptoms, represent up to 20-30% of older adults in cohort studies and are linked to future cognitive decline, often involving small subcortical lesions. Refinements in cryptogenic classification, such as embolic of undetermined source (ESUS) defined in 2014, identify a subset of non-lacunar infarcts with embolic features but no identified source, comprising 15-25% of ischemic strokes. However, subsequent randomized controlled trials, including NAVIGATE-ESUS, RE-SPECT ESUS, and ARCADIA, did not demonstrate superiority of direct oral anticoagulants over aspirin in preventing recurrent and showed increased risk; current guidelines recommend antiplatelet therapy for most ESUS patients. In 2025, the Ischemic Stroke Phenotyping System (ISPS25) was proposed as an updated framework to enhance subtyping through expanded minimum diagnostic evaluations, potentially reclassifying patients for improved secondary prevention.

Etiology and risk factors

Cerebral infarction primarily results from thrombotic or embolic occlusion of , leading to reduced blood flow and tissue ischemia. Large-artery , characterized by plaque accumulation and rupture in major vessels such as the carotid arteries, accounts for approximately 20-25% of cases and often involves thrombi formation or distal . Cardioembolic events, originating from cardiac sources like or , contribute to about 20% of ischemic strokes by dislodging emboli into the . Small vessel disease, driven by hypertensive , leads to lacunar infarcts in subcortical regions and represents around 25% of cases, particularly in individuals with chronic or . Less common etiologies include arterial , which may occur spontaneously or post-trauma, and hypercoagulable states such as , each comprising under 5% of infarctions but requiring specific diagnostic evaluation. Modifiable risk factors play a central role in the development of cerebral infarction, with hypertension being the most significant, carrying an of approximately 3.0 for ischemic and a population-attributable (PAF) of 39-60% across global populations. nearly doubles the risk ( ~1.9) and has a PAF of 4-18% depending on regional prevalence, while diabetes mellitus confers a twofold increased risk ( ~2.0) with a PAF contributing to about 10% of burden when combined with other factors. elevates risk through accelerated , with therapy reducing ischemic incidence by 11-40%, and further amplifies susceptibility by promoting and . Non-modifiable risk factors include advancing age, where incidence doubles every decade after 55 years, and male sex, which confers higher risk at younger ages despite women's overall greater lifetime incidence due to longevity. Family history of stroke increases susceptibility through shared genetics, while ethnic disparities show African Americans facing a 50-100% higher risk compared to non-Hispanic whites, and South Asian populations experiencing elevated rates of small vessel disease. Emerging factors include obstructive sleep apnea, which independently raises ischemic stroke risk (hazard ratio 2.5), air pollution with long-term PM2.5 exposure linked to a 10-20% increased risk per 10 μg/m³ increment, and prior SARS-CoV-2 infection, associated with 1.8-fold higher odds of ischemic stroke particularly in severe cases. Genetic markers like Factor V Leiden mutation modestly elevate risk in young adults (odds ratio 2.0), especially in prothrombotic contexts.

Pathophysiology

Mechanisms of ischemia

Cerebral blood flow is tightly regulated to meet the brain's high metabolic demands, with normal flow rates averaging 50-60 mL/100 g/min under physiological conditions. maintains stable perfusion by adjusting in response to changes in , typically within a range of 60-150 mmHg, where blood flow remains constant despite fluctuations in systemic pressure. This mechanism involves myogenic responses in arterioles and metabolic feedback from brain tissue. Collateral circulation, primarily through the circle of Willis—an anastomotic ring connecting the major —provides alternative pathways to redistribute blood flow when primary vessels are compromised, potentially mitigating ischemia in affected territories. Ischemia in cerebral infarction arises from disruptions in this regulated blood supply, primarily through three mechanisms: , , and . involves local clot formation within , often at sites of atherosclerotic plaque, leading to abrupt and downstream hypoperfusion. occurs when thrombi or other particles, such as from cardiac sources or proximal arterial plaques, travel and lodge in distal cerebral vessels, causing sudden territorial ischemia. Hypoperfusion results from global or regional reductions in blood flow, such as during systemic from or severe extracranial , overwhelming compensatory autoregulation and collaterals. Underlying vascular pathology contributes to these triggers, particularly and in , a common precipitant of ischemic events. impairs , promotes , and facilitates formation by altering the wall's properties. , characterized by thin fibrous caps and lipid-rich cores, increases the risk of rupture, releasing embolic debris or triggering in situ . Hemodynamic failure becomes critical in cases of significant , such as greater than 70% narrowing in the , where flow limitation exceeds collateral capacity, heightening risk as demonstrated in symptomatic patients. Quantitative thresholds define the progression from reversible to irreversible ischemia based on cerebral blood flow (CBF) reductions. The infarct core, where irreversible death occurs, develops when CBF falls below approximately 10-12 mL/100 g/min for a sufficient duration. The ischemic penumbra represents a surrounding zone of viable but compromised with CBF between approximately 12-20 mL/100 g/min, where neuronal function is impaired but is not inevitable, offering a window for therapeutic salvage if is restored promptly.

Ischemic cascade

The refers to the sequential series of biochemical and cellular events triggered by cerebral ischemia in the setting of cerebral infarction, leading to progressive neuronal injury if blood flow is not restored. This process begins rapidly after the onset of reduced cerebral blood flow and unfolds over minutes to days, highlighting the critical time for potential interventions to limit damage. In the hyperacute phase, occurring within 0-30 minutes of ischemia onset, the primary event is energy failure due to oxygen and glucose deprivation, resulting in rapid ATP depletion to approximately 0-25% of normal levels. This ATP shortfall inhibits the Na⁺/K⁺-ATPase pump, which normally maintains ionic gradients by hydrolyzing ATP to exchange intracellular Na⁺ for extracellular K⁺; the basic model of this failure can be represented as pump activity ceasing when ATP falls below a critical , leading to membrane depolarization and cytotoxic from Na⁺ and water influx. Anaerobic metabolism predominates, producing that further acidifies the intracellular environment and exacerbates energy deficits. The acute phase, spanning 30 minutes to 6 hours, involves driven by excessive glutamate release from depolarized neurons, which overactivates NMDA and receptors, causing massive calcium influx into cells. This calcium overload activates proteases, lipases, and endonucleases, promoting free radical formation—such as (ROS)—that damage lipids, proteins, and DNA, while also initiating (BBB) breakdown through . In embolic subtypes, this progression may accelerate due to abrupt occlusion, intensifying early excitotoxic damage. During the subacute phase from 6 to 72 hours, escalates with microglial activation and release (e.g., TNF-α, IL-1β), recruiting peripheral leukocytes that amplify tissue injury and contribute to vasogenic edema via further permeability. mechanisms diverge here: predominates in the severely ischemic core due to uncontrolled swelling and , while —a pathway involving activation—occurs more in marginally affected regions, allowing for potential salvage. Central to the cascade is the ischemic penumbra, a rim of viable but hypoperfused surrounding the infarct , where cells maintain electrophysiological silence but retain metabolic potential for recovery if reperfused promptly. In the , irreversible neuronal death typically completes within 4-6 hours, but the penumbra offers a therapeutic window, as delayed intervention can still mitigate expansion into this salvageable zone.

Clinical presentation

Signs and symptoms

Cerebral infarction, a type of ischemic stroke, typically presents with sudden onset of focal neurological deficits corresponding to the affected vascular territory in the brain. These symptoms arise due to ischemia-induced neuronal dysfunction and can vary based on the location and extent of the infarction. Focal symptoms often reflect the specific brain region involved. In middle cerebral artery (MCA) infarctions, common manifestations include contralateral hemiparesis affecting the face and upper extremities more than the lower limbs, sensory loss in the same distribution, aphasia or neglect depending on the dominant or nondominant hemisphere, and gaze deviation toward the lesion side. Anterior cerebral artery (ACA) infarcts typically cause contralateral weakness and sensory deficits predominantly in the lower extremities, with relative sparing of the face and arms, sometimes accompanied by urinary incontinence or abulia. Posterior cerebral artery (PCA) territory involvement leads to contralateral homonymous hemianopia, often with macular sparing, along with possible thalamic sensory disturbances, memory impairment, or cortical blindness in bilateral cases. Posterior circulation infarcts, such as those in the vertebrobasilar system or cerebellum, may produce ataxia, vertigo, dysarthria, diplopia, and limb incoordination, with ataxia being prominent in cerebellar lesions. Non-focal or global symptoms can occur, particularly with larger infarcts or those causing . Altered mental status, ranging from to , may develop due to increased or widespread ischemia. is less frequent in cerebral infarction compared to hemorrhagic , occurring in about 25% of cases, and is often mild unless associated with posterior circulation involvement. Symptom progression patterns vary; most infarcts reach maximal deficit at onset, but stuttering or stepwise worsening can occur over hours to days due to evolving ischemia or . Lacunar infarcts, resulting from occlusion of small penetrating arteries, produce characteristic syndromes without cortical involvement. Pure motor hemiparesis involves contralateral facial, arm, and leg weakness without sensory or visual deficits, often due to lesions. Pure sensory stroke causes numbness or paresthesia on the contralateral side, typically from thalamic involvement. Ataxic hemiparesis combines hemiparesis with ipsilateral ataxia, commonly from pontine or capsular infarcts. Variations in presentation include silent infarcts, which occur without noticeable symptoms and are detected incidentally on , accounting for 10% to 30% of cerebral s in older adults. Transient symptoms lasting less than 24 hours, distinguishing transient ischemic attacks (TIAs) from , may mimic these signs but resolve fully. Quick recognition aids like the FAST (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services) can help identify potential symptoms.

Recognition and assessment

The recognition and assessment of cerebral infarction in acute settings rely on rapid, standardized screening tools to identify potential symptoms and facilitate timely intervention. The FAST acronym (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services) serves as a widely adopted prehospital and public education tool derived from the , enabling quick identification of key focal neurological deficits. An enhanced version, BE-FAST, incorporates additional checks for Balance loss and Eye deviation or vision changes, improving sensitivity for posterior circulation strokes and vertigo-related presentations without compromising specificity. In clinical and prehospital evaluation, determining the exact time of symptom onset or last known normal is critical to establish eligibility for time-sensitive therapies, often achieved through patient history or accounts. Common stroke mimics, such as seizures or migraines, must be excluded via targeted questioning and basic neurological checks to avoid misdiagnosis, as these conditions can present with unilateral weakness or sensory changes. Prehospital protocols emphasize (EMS) activation within minutes of symptom recognition, with guidelines targeting on-scene times of 15 minutes or less to expedite transport to stroke-capable facilities. The urgency of assessment is underscored by the "time is brain" principle, which quantifies irreversible neuronal loss at approximately 1.9 million neurons per minute of untreated ischemia, equating to substantial if delays occur. Hospital protocols aim for door-to-needle times of 60 minutes or less for eligible thrombolytic administration, a associated with improved functional outcomes. The Stroke Scale (NIHSS) provides a structured quantification of deficits such as those in facial or speech, with scores ranging from 0 (no ) to 42 (severe); scores exceeding 4 typically indicate moderate severity warranting escalated . Recent advancements include mobile stroke units (MSUs), specialized ambulances equipped for prehospital and laboratory testing, introduced in trials post-2010. These units have demonstrated reductions in treatment delays by 25-90 minutes compared to standard , enabling earlier decisions and better outcomes in randomized studies like PHANTOM-S and BEST-MSU.

Diagnosis

Clinical evaluation

The clinical evaluation of cerebral infarction begins with a thorough history to determine the precise timing of symptom onset, which is essential for assessing eligibility for time-sensitive interventions. Elicitation of modifiable and non-modifiable risk factors, including , diabetes mellitus, , , smoking, and family history, helps identify underlying etiologies and guide secondary prevention. Inquiry into prior transient ischemic attacks (TIAs) or strokes is critical, as recurrent events may indicate specific vascular pathologies. When the patient cannot provide a reliable account due to , , or , collateral history from witnesses, family, or prehospital personnel is obtained to clarify the timeline and circumstances. A systematic physical examination follows, encompassing both general and neurological components. The general examination focuses on , cardiac to detect irregular rhythms suggestive of , and of the carotid arteries for bruits indicating or plaque. The systematically assesses mental status, cranial nerve function (e.g., pupillary responses, extraocular movements, facial symmetry), motor strength in all limbs, sensory integrity, deep tendon reflexes, plantar responses, coordination, and cerebellar function to localize the infarcted territory and gauge deficit severity. Standardized tools are employed to quantify and characterize impairments. The Scale (NIHSS), a validated 15-item instrument, measures severity with high and supports localization; for instance, high scores on facial palsy and arm drift items often suggest middle cerebral artery territory involvement. In patients with depressed consciousness, the (GCS) evaluates eye opening, verbal response, and motor response to stratify depth and predict prognosis. Differential diagnosis is integral to avoid misclassification, distinguishing cerebral infarction from mimics such as (which may feature more severe headache or vomiting at onset), (prompting immediate bedside glucose measurement), and Todd's paralysis (a postictal focal weakness resolving within hours). Building on initial recognition tools like the , this evaluation refines suspicion through detailed and exam findings. In resource-limited or rural settings, tele-stroke consultations have seen significant expansion during the , enabling real-time expert review of history and examination via videoconferencing to enhance diagnostic accuracy and expedite care decisions.

Imaging and laboratory tests

Non-contrast computed tomography () of the head is the initial imaging modality of choice for suspected cerebral infarction, primarily to exclude and identify early signs of ischemia, such as loss of gray-white matter differentiation or hypoattenuation. Non-contrast computed tomography () of the head should be completed within 20 minutes of patient arrival (door-to-CT time), with interpretation by a with stroke expertise occurring within 20 minutes of scan completion, facilitating rapid decision-making for thrombolytic therapy eligibility. The Alberta Stroke Program Early CT Score (ASPECTS), ranging from 0 to 10, quantifies the extent of early ischemic changes in the middle cerebral artery territory on non-contrast , with scores below 6 indicating larger infarcts associated with poorer outcomes. Magnetic resonance imaging (MRI), particularly diffusion-weighted imaging (DWI), offers superior sensitivity for detecting acute cerebral infarction, identifying cytotoxic edema with over 95% sensitivity within minutes of onset, compared to non-contrast CT's lower early detection rate of approximately 67% within 3 hours. DWI is especially useful for confirming ischemia in cases where CT is inconclusive or for assessing small infarcts, though MRI is not routinely first-line due to longer acquisition times. Fluid-attenuated inversion recovery (FLAIR) sequences complement DWI to better delineate infarct age. Vascular imaging, such as CT (CTA) or MR (MRA), is recommended to evaluate for large vessel occlusions, which occur in up to 20-30% of acute ischemic strokes and guide endovascular interventions. CTA demonstrates high accuracy for intracranial occlusions (sensitivity 92-100%, specificity 82-100%), while MRA serves as a non-contrast alternative. Carotid Doppler ultrasound noninvasively assesses extracranial , quantifying plaque burden and flow velocities to identify sources of , with sensitivity exceeding 90% for hemodynamically significant stenoses greater than 70%. Perfusion imaging via or techniques identifies the ischemic penumbra—the potentially salvageable tissue surrounding the infarct core—by mapping cerebral blood flow, , and transit time mismatches. This modality extends the therapeutic window beyond 4.5 hours in select patients, as validated in trials like DAWN and DEFUSE 3, where penumbra assessment predicted favorable outcomes with up to 24 hours. remains the gold standard for detailed intracranial vessel evaluation during endovascular planning, though it is invasive and reserved for procedural guidance. Recent advancements, including AI-assisted tools for automated ASPECTS calculation and large vessel occlusion detection on CT/CTA, have reduced interpretation times by up to 50%, aligning with 2023 recommendations for integrating such technologies to expedite workflows in high-volume centers. Laboratory evaluation in suspected cerebral infarction focuses on excluding contraindications to , assessing comorbidities, and identifying underlying etiologies. A (CBC) is essential to detect or , which could increase hemorrhagic risk, and should be obtained immediately upon arrival. studies, including (PT), international normalized ratio (INR), and activated (aPTT), are critical for thrombolytic eligibility, with INR greater than 1.7 typically contraindicating intravenous alteplase. Blood glucose measurement is mandatory to rule out hypo- or mimicking symptoms, targeting levels between 140-180 mg/dL in acute management. Additional routine tests include serum electrolytes, renal function (blood urea nitrogen and ), and to evaluate metabolic derangements and cardiovascular risk factors. Cardiac biomarkers such as are recommended to screen for concomitant myocardial injury or embolic sources from . In younger patients (typically under 50 years) without traditional risk factors, a hypercoagulable panel—including antiphospholipid antibodies, /S, III, and —is warranted to identify inherited or acquired thrombophilias contributing to 5-10% of such cases. All initial labs should be completed with results available no later than 30 minutes after arrival to avoid delaying imaging or therapy, with considered if standard turnaround times cannot meet this target.

Treatment

Acute interventions

Intravenous thrombolysis with (tPA) is a cornerstone of acute intervention for eligible patients with cerebral infarction, administered within 4.5 hours of symptom onset to restore blood flow and minimize ischemic damage. The recommended dose is 0.9 mg/kg (maximum 90 mg), with 10% given as an initial bolus over 1 minute followed by infusion of the remainder over 60 minutes. Eligibility requires confirmation of ischemic stroke via non-contrast to exclude hemorrhage, with contraindications including active , recent major , or such as an INR greater than 1.7. For patients with large vessel occlusions (LVOs), such as those in the (ICA) or (MCA), endovascular mechanical using stent retrievers offers a highly effective reperfusion strategy, particularly when is insufficient or contraindicated. The DAWN trial demonstrated significant functional improvement with performed 6 to 24 hours after last known well in patients selected by perfusion showing a mismatch between infarct core and penumbra. Similarly, the DEFUSE-3 trial extended the window to 6 to 16 hours for anterior circulation LVOs, showing superior outcomes with endovascular therapy plus medical management compared to medical management alone. These procedures are guided by multimodal to ensure a favorable mismatch ratio, prioritizing rapid intervention to achieve recanalization rates exceeding 80% in selected cases. Supportive measures in the hyperacute phase focus on optimizing physiological parameters to facilitate safe reperfusion. should be managed to below 185/110 mmHg prior to and during tPA administration to reduce hemorrhage risk, using agents like or if needed. In patients not receiving tPA, aspirin at a dose of 325 mg is recommended within 48 hours of onset to prevent early recurrent ischemia, unless contraindicated by . In 2025, the time window was further extended for selected patients based on ; for instance, trials such as and studies on posterior circulation strokes demonstrated benefits of intravenous ( or ) from 4.5 to 24 hours after symptom onset in patients with evidence of salvageable penumbra via mismatch. Tenecteplase, a fibrin-specific thrombolytic administered as a single 0.25 mg/kg bolus, was approved by the U.S. in March 2025 for the treatment of acute ischemic in adults and has shown non-inferiority (and in some cases superiority) to in achieving excellent functional outcomes at 90 days in multiple phase 3 trials. For instance, the trial and pooled analyses confirmed comparable safety profiles, with potential advantages in ease of administration for prehospital settings. Efforts in , such as the free radical scavenger NXY-059, have largely failed; the SAINT-II trial showed no benefit in reducing when added to tPA within 6 hours of onset.

Rehabilitation and long-term care

Rehabilitation following cerebral infarction typically begins early in the acute phase to optimize recovery and minimize secondary complications. Early mobilization in the , initiated within 24 to 48 hours for medically stable patients, involves gentle to reduce the risk of , , and . This phase transitions to inpatient , where multidisciplinary interventions such as for mobility, for daily activities, and speech-language therapy for communication and swallowing impairments are provided intensively, often in specialized units. Outpatient extends these efforts for 3 to 6 months post-discharge, focusing on reintegration and sustained functional gains through tailored exercise programs. Specific therapeutic approaches target common deficits like and . Constraint-induced movement therapy (CIMT) restricts the unaffected limb to encourage intensive use of the paretic arm, demonstrating significant improvements in upper extremity function for chronic patients with moderate impairment. screening, using validated bedside tools like the Toronto Bedside Swallow Screen, is performed immediately upon stabilization to identify aspiration risk and prevent , with early screening reducing the risk of by approximately 40% (OR 0.60) in acute patients. Psychological support is integral, addressing post- depression, which affects approximately 30% of survivors in the first year, through and antidepressants to enhance adherence to . Long-term care emphasizes multidisciplinary teams comprising physicians, therapists, nurses, and social workers to coordinate ongoing management and prevent recurrent events or complications such as . Assistive devices, including , wheelchairs, and adaptive utensils, are prescribed based on individual needs to promote independence in . Resumption of driving requires a minimum 1-month abstinence post-, with clearance typically after 3 to 6 months contingent on comprehensive cognitive, visual, and motor evaluations to ensure safety. Recent advancements include the expansion of telerehabilitation, accelerated by the in the , which delivers remote physical and occupational therapy via video platforms, achieving comparable outcomes to in-person sessions while improving access for rural patients. Experimental stem cell therapies, such as allogeneic mesenchymal stem cells administered intravenously, are in phase II/III trials as of 2025, showing preliminary safety and potential for neuroregeneration in subacute ischemic stroke without established efficacy.

Prognosis and prevention

Outcomes and complications

The prognosis following cerebral infarction depends on factors such as infarct size, location, initial severity, and patient comorbidities, with outcomes ranging from full to significant or . Short-term mortality is substantial, with 10-20% of patients succumbing within 30 days, and rates exceeding 30% in cases of large-vessel or extensive infarcts. Long-term survival improves but remains guarded; for instance, overall survival probability is approximately 82% at 3 months and 77% at 1 year for first-ever ischemic strokes. Globally, ischemic accounts for 7.8 million incident cases annually, with 3.6 million deaths and 70.4 million disability-adjusted life years lost. Functional recovery is commonly evaluated using the (), a 7-point ordinal scale from 0 (no symptoms) to 6 (death), focusing on in daily activities. At 3 months, roughly 50% of survivors achieve independence ( 0-2), though this drops in severe cases, with only 20-30% reaching good outcomes in large infarcts. The risk of recurrent is notable, affecting about 8-10% of patients in the first year, often linked to inadequate secondary prevention. Intravenous tissue plasminogen activator (tPA) administration can enhance the odds of a favorable score by around 30% relative to in eligible patients. Complications of cerebral infarction can arise acutely or persist long-term, significantly impacting survival and . Early adverse events include hemorrhagic transformation, a breakdown of the blood-brain barrier leading to bleeding into the infarcted area; after tPA , symptomatic cases occur in approximately 6% of patients, often worsening neurological deficits. Vascular complications such as deep vein thrombosis (DVT) develop in 10-20% of immobilized patients without prophylactic anticoagulation, increasing the risk of . Late complications frequently involve neurocognitive and neuropsychiatric sequelae. Post-stroke affects 20-30% of survivors within the first year, doubling the risk compared to age-matched controls without . emerges in 5-10% of cases, typically within the first 1-2 years, with higher incidence in cortical infarcts. complicates recovery in 30-50% of patients, correlating with poorer functional outcomes and reduced adherence to . Key predictors of poor prognosis include high initial stroke severity, as indicated by a National Institutes of Health Stroke Scale (NIHSS) score greater than 16, which is associated with over 50% risk of death or severe disability at 3 months. Advanced age over 80 years halves the odds of achieving functional independence compared to younger adults, due to reduced and comorbidities. Socioeconomic and factors exacerbate outcomes, with racial and ethnic minorities—particularly Black Americans—experiencing worse neurologic, functional, and cognitive recovery at 90 days, often due to disparities in access to timely care. During the COVID-19 era, outcomes worsened, with infected patients showing increased severity (higher NIHSS scores at admission) and mortality rates up to 2-3 times higher than non-infected counterparts, attributed to hypercoagulability and delayed treatments. post-infarction is notably diminished, as reflected in health survey scores, where survivors typically score 20-30 points lower on physical and mental component summaries than population norms, with persistent deficits in and emotional well-being.

Preventive strategies

Primary prevention of cerebral infarction focuses on modifiable risk factors through lifestyle interventions and targeted screening. is a cornerstone, as quitting use can reduce the risk of by up to 50% within five years, approaching levels seen in never-smokers. Adopting a and regular to maintain a below 25 kg/m² further lowers risk by addressing obesity-related and . control to below 130/80 mmHg is critical, with evidence showing that achieving this target through lifestyle changes and prevents a significant portion of first-time . For individuals at elevated risk, such as those with history, screening via is recommended if exceeds 50%, enabling interventions like to mitigate embolic events. Secondary prevention targets those with prior cerebral infarction or to avert recurrence. Antiplatelet therapy is standard, with low-dose aspirin (81 mg daily) or clopidogrel (75 mg daily) recommended to inhibit platelet aggregation and reduce ischemic events by 20-25%. For patients with , direct oral anticoagulants (DOACs) such as are preferred over ; the trial demonstrated apixaban's superiority in preventing or systemic (hazard ratio 0.79) with lower bleeding risk. High-intensity therapy, aiming for low-density lipoprotein cholesterol below 70 mg/dL, is advised to stabilize atherosclerotic plaques and decrease recurrent risk by 16-22%, as shown in the Treat Stroke to Target trial. Public health measures complement individual efforts. Annual influenza vaccination reduces stroke risk by approximately 20-30%, particularly in high-risk groups, by mitigating infection-triggered and . Population-level policies, such as salt reduction campaigns, promote lower sodium intake (target <2 g/day), which can prevent up to 83,000 stroke deaths over a decade by curbing prevalence. Current guidelines from the /American Stroke Association (AHA/ASA 2024) emphasize integrated approaches, including screening for sedentary behavior and , with sodium-glucose cotransporter-2 (SGLT2) inhibitors for diabetic patients to reduce cardiovascular events, including , by 14% compared to other glucose-lowering agents. For refractory , emerging therapies like inhibitors (e.g., ) further lower LDL by 50-60% and risk by 25%, offering benefits when statins alone are insufficient.

References

  1. [1]
    Ischemic Stroke - StatPearls - NCBI Bookshelf - NIH
    Feb 21, 2025 · Ischemic stroke, the most common type of stroke, is caused by thrombotic or embolic occlusion that reduces blood flow to the brain. The ...
  2. [2]
    Stroke - Symptoms and causes - Mayo Clinic
    Dec 13, 2024 · An ischemic stroke occurs when the blood supply to part of the brain is blocked or reduced. This prevents brain tissue from getting oxygen ...
  3. [3]
    Stroke - Diagnosis and treatment - Mayo Clinic
    Dec 13, 2024 · In the most common type of stroke, called an ischemic stroke, or cerebral infarction, there's a lack of blood flow to an area of the brain ...
  4. [4]
    Proposal for a universal definition of cerebral infarction - PubMed - NIH
    Aug 14, 2008 · This review proposes cerebral infarction be defined as brain or retinal cell death due to prolonged ischemia.
  5. [5]
  6. [6]
    An Updated Definition of Stroke for the 21st Century - PubMed Central
    Stroke is classically characterized as a neurological deficit attributed to an acute focal injury of the central nervous system (CNS) by a vascular cause, ...
  7. [7]
    World Stroke Organization: Global Stroke Fact Sheet 2025 - PMC
    There are over 7.8 million new ISs each year. Globally, about 65% of all incident strokes are ISs.
  8. [8]
  9. [9]
    Global burden of stroke in adolescents and young adults (aged 15 ...
    Jul 30, 2024 · A concerning trend of increasing ischemic stroke incidence, DALYs, and prevalence rates has emerged in the global 15-39 age group, especially among those aged ...
  10. [10]
    Stroke in Young Adults - PMC - NIH
    Jul 29, 2023 · In the US, the incidence of stroke for adults aged 20–44 has increased from 17 per 100,000 US adults in 1993 to 28 per 100,000 US adults in 2015 ...
  11. [11]
    Apoplexy, cerebrovascular disease, and stroke: Historical evolution ...
    Hippocrates (and the Hippocratic Corpus) is responsible for the first recorded appearance of the term “apoplexy”. The concept is mentioned in several parts of ...
  12. [12]
    Western Christianity's two historical treatments of people with ...
    The prevailing view for much of history has been that illness was divinely ordained as punishment for sin. Transgressions against God's resulted in the ...
  13. [13]
    Johannes Jacob Wepfer (1620-1695) - Hektoen International
    Oct 28, 2021 · From these he showed that apoplexy was caused by cerebral hemorrhage.3 In Historiae apoplecticorum, published in 1658 is a detailed description ...Missing: pathology | Show results with:pathology
  14. [14]
    Apoplexy, cerebrovascular disease, and stroke: Historical evolution ...
    Hippocrates (and the Hippocratic Corpus) is responsible for the first recorded appearance of the term “apoplexy”. The concept is mentioned in several parts of ...<|control11|><|separator|>
  15. [15]
    Rudolf Virchow and the Discovery of Cerebral Embolism | Stroke
    May 24, 2021 · He introduced the term thrombosis for the whole process. The pathology in the damaged lung varied. There could be congestion and hemorrhage, or ...Missing: infarction | Show results with:infarction
  16. [16]
    Virchow Triad - StatPearls - NCBI Bookshelf
    In 1856, Rudolf Virchow, a renowned Berlin ... In theory, Virchow's triad postulates 3 factors predisposing a person to develop vascular thrombosis.
  17. [17]
    Milestones in CT: Past, Present, and Future - PMC - NIH
    In 1971, the first patient CT exam by Ambrose and Hounsfield paved the way for not only volumetric imaging of the brain but of the entire body.
  18. [18]
    Tissue Plasminogen Activator for Acute Ischemic Stroke
    Treatment with intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months.
  19. [19]
    A Randomized Trial of Intraarterial Treatment for Acute Ischemic ...
    Dec 17, 2014 · Intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others)
  20. [20]
    Population Impact of Potentially Modifiable Risk Factors for Stroke
    Feb 12, 2020 · Hypertension was by far the most potent risk factor, being associated with 91% (88%–94%) of the PAF of stroke among individuals of African ...
  21. [21]
    Stroke Risk Factors, Genetics, and Prevention | Circulation Research
    Feb 3, 2017 · Nonmodifiable risk factors (also called risk markers) for stroke include age, sex, race-ethnicity, and genetics. In general, stroke is a disease ...Nonmodifiable Stroke Risk... · Modifiable Risk Factors · Targeted Lifestyle...
  22. [22]
    Stroke and Black/African Americans - HHS Office of Minority Health
    Stroke and Black/African Americans. In 2018, non-Hispanic Black or African American adults were 50% more likely to have a stroke than non-Hispanic white adults.
  23. [23]
    Obstructive Sleep Apnea as a Risk Factor for Stroke and Death
    Nov 10, 2005 · The obstructive sleep apnea syndrome significantly increases the risk of stroke or death from any cause, and the increase is independent of other risk factors, ...
  24. [24]
    Long-Term Exposure to Particulate Matter Air Pollution Is a Risk ...
    Oct 13, 2015 · These meta-analyses suggested a small but significant effect of recent PM exposure and the risk of stroke in general and ischemic stroke in ...
  25. [25]
    Meta-Analysis of Factor V Leiden and Ischemic Stroke in Young Adults
    Jul 8, 2010 · Factor V Leiden is the most common prothrombotic genetic predisposition. It is present in 5.2% of whites and 1.2% of blacks, although it is more ...
  26. [26]
    Influence of Changes in Blood Pressure on Cerebral Perfusion and ...
    In 1959, Lassen established that CBF in humans is independent of changes in mean arterial blood pressure (MAP) within a range of ≈60 to 150 mm Hg; and this has ...
  27. [27]
    Collateral Circulation | Stroke - American Heart Association Journals
    The cerebral collateral circulation refers to the subsidiary network of vascular channels that stabilize cerebral blood flow when principal conduits fail.
  28. [28]
    Stroke pathophysiology | STROKE MANUAL
    Dec 5, 2024 · Ischemic Stroke is caused by the occlusion of cerebral arteries due to embolism, thrombosis, or systemic hypoperfusion.<|control11|><|separator|>
  29. [29]
    Endothelial Dysfunction in the Brain: Setting the Stage for Stroke ...
    The endothelium has a pivotal role in cerebrovascular disease. Endothelial dysfunction occurs after stroke and leads to oxidative stress, inflammation, ...Abstract · Ace2 As A Target Of... · Figure
  30. [30]
    Atherosclerotic Plaque Instability and Rupture
    Sep 24, 2025 · Atherosclerotic plaque instability/rupture is the major driver of myocardial infarction and stroke, the leading causes of cardiovascular ...
  31. [31]
    Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients ...
    Aug 15, 1991 · Patients with high-grade stenosis (70 to 99 percent) should be considered for referral to institutions and surgeons who practice vigorous ...
  32. [32]
    Perfusion thresholds in human cerebral ischemia - PubMed
    In a series of PET studies performed 5--18 h after stroke onset, we have determined the threshold for penumbra to be around 20 ml/100 g/min, and documented ...
  33. [33]
    Pathophysiologic cascades in ischemic stroke - PMC
    In this minireview, we summarize the basics of ischemic cascades after stroke, covering neuronal death mechanisms, white matter pathophysiology, and ...
  34. [34]
  35. [35]
    Ischemic Stroke: Background, Anatomy, Pathophysiology
    Feb 21, 2024 · Acute ischemic stroke is caused by thrombotic or embolic occlusion of a cerebral artery. (See the image below.) Maximum intensity projection ...
  36. [36]
    Ischemic Stroke: Pathophysiology and Evolving Treatment ...
    Oct 22, 2024 · This review provides an overview of ischemic stroke pathophysiology, emphasizing cellular responses to ischemia and current and future therapeutic approaches.
  37. [37]
  38. [38]
    Anterior Cerebral Artery Stroke - StatPearls - NCBI Bookshelf - NIH
    Anterior cerebral artery strokes occur in the territory of the anterior cerebral artery which involves the superior and medial part of the parietal lobe.
  39. [39]
    Cerebellar Infarct - StatPearls - NCBI Bookshelf - NIH
    Cerebellar infarcts are acute ischemic stroke subtypes caused by the occlusion of 1 of the 3 main cerebellar branches of the vertebrobasilar arterial system ...
  40. [40]
    Progression in Acute Stroke | Stroke
    Clinical observations suggest that the first 48 hours after an ischemic stroke are associated with potential instability and secondary worsening. Work in the ...Missing: patterns | Show results with:patterns
  41. [41]
    Lacunar infarcts - UpToDate
    Apr 15, 2025 · Lacunar syndromes · Pure motor hemiparesis · Pure sensory stroke · Ataxic hemiparesis · Sensorimotor stroke · Dysarthria-clumsy hand syndrome ...
  42. [42]
    Covert Brain Infarction | Stroke - American Heart Association Journals
    Jul 10, 2020 · CBIs are defined as focal lesions detected on brain imaging for which brain ischemia seems the most likely explanation (see probability ...
  43. [43]
    Signs and Symptoms of Stroke - CDC
    Oct 24, 2024 · Sudden trouble seeing in one or both eyes. Sudden trouble walking, dizziness, loss of balance, or lack of coordination. Sudden severe headache ...
  44. [44]
    BE-FAST (Balance, Eyes, Face, Arm, Speech, Time) | Stroke
    Jan 12, 2017 · The FAST algorithm (Face, Arm, Speech, Time) helps identify persons having an acute stroke. We determined the proportion of patients with acute ...
  45. [45]
    BE FAST Versus FAST: A Randomized Pilot Trial Comparing ...
    Sep 18, 2024 · The FAST acronym (Face, Arm, Speech, Time) was derived from the Cincinnati Prehospital Stroke Scale and was adopted by the American Heart ...
  46. [46]
  47. [47]
    Bedside assessment of stroke and stroke mimics - PMC
    Every study on stroke mimics identifies seizures and post-seizure events as common causes of stroke-like conditions. Traditional thought is that these postictal ...
  48. [48]
  49. [49]
    Time is brain--quantified - PubMed
    The phrase "time is brain" emphasizes that human nervous tissue is rapidly lost as stroke progresses and emergent evaluation and therapy are required.Missing: concept | Show results with:concept
  50. [50]
    Introducing Target: Stroke Phase III | American Heart Association
    Achieve door-to-needle times within 60 minutes in 85 percent or more of acute ischemic stroke patients treated with IV thrombolytics. Achieve door-to-device ...
  51. [51]
    NIH Stroke Scale - Physiopedia
    Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as ...Objective · Method of Use · Evidence
  52. [52]
    What is the NIH Stroke Scale? - Baptist Health
    Sep 26, 2018 · Assessing Stroke Severity · 0 = No stroke symptoms · 1-4 = Minor stroke · 5-15 = Moderate stroke · 16-20 = Moderate to severe stroke · 21-42 = Severe ...Nih Stroke Scale · Assessing Stroke Severity · Related Blog Articles
  53. [53]
    Prospective, Multicenter, Controlled Trial of Mobile Stroke Units
    Sep 8, 2021 · In patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS.
  54. [54]
    In What Scenarios Does a Mobile Stroke Unit Predict Better Patient ...
    May 11, 2020 · Across several studies, MSU utilization has reduced median first medical contact-to-needle time between 29 and 48 minutes (study dependent).
  55. [55]
    Guidelines for the Early Management of Patients With Acute ...
    Oct 30, 2019 · These guidelines provide general recommendations based on the currently available evidence to guide clinicians caring for adult patients with ...
  56. [56]
    Recommendations for Imaging of Acute Ischemic Stroke
    MRI is superior to CT for demonstration of subacute and chronic hemorrhage and hemorrhagic transformation of an acute ischemic stroke (LOE: B).
  57. [57]
    Usefulness of Carotid Ultrasonography for Risk Stratification of ...
    Carotid ultrasonography is useful for the assessments of the risk stratification for stroke or coronary artery disease, because it is a simple, repeatable, and ...
  58. [58]
    Performance of an artificial intelligence tool for multi-step acute ...
    Aug 29, 2025 · This study evaluated the performance of an FDA-cleared and CE-marked AI tool to assist clinicians across every step of the stroke imaging ...
  59. [59]
    The Clinical Approach to Stroke in Young Adults - NCBI
    All young stroke patients should undergo urine toxicology testing on admission. ... panel assessing for genetic thrombophilias in young stroke patients. One ...
  60. [60]
  61. [61]
    Scientific Rationale for the Inclusion and Exclusion Criteria for ...
    Dec 22, 2015 · In most published stroke studies on INR levels and intravenous alteplase, INR >1.7 is attributable to medication effect and not attributable ...
  62. [62]
    Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between ...
    Nov 11, 2017 · The DAWN trial was a multicenter, prospective, randomized, open-label trial with a Bayesian adaptive–enrichment design and with blinded ...
  63. [63]
    Thrombectomy for Stroke at 6 to 16 Hours with Selection by ...
    Jan 24, 2018 · The DEFUSE 3 trial was a randomized, open-label trial, with blinded outcome assessment, that compared endovascular therapy plus standard medical ...
  64. [64]
    Blood Pressure Management for Ischemic Stroke in the First 24 Hours
    Mar 16, 2022 · The current American Heart Association/American Stroke Association and ESO guidelines recommend maintaining BP below 185/110 mm Hg for patients ...
  65. [65]
    2018 AHA/ASA Stroke Early Management Guidelines
    May 9, 2018 · IV tPA should be administered to all eligible acute stroke patients within 3 hours of last known normal and to a more selective group of ...
  66. [66]
    Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke
    Sep 12, 2024 · Tenecteplase was noninferior to alteplase with respect to excellent functional outcomes (mRS score of 0 or 1) at 90 days in patients with AIS ...
  67. [67]
    Comprehensive Review of Tenecteplase for Thrombolysis in Acute ...
    Apr 30, 2024 · The latest 2023 European Stroke Organisation guideline strongly recommended that 0.25 mg/kg tenecteplase can be used as an alternative to 0.9 mg ...
  68. [68]
    NXY-059 for the Treatment of Acute Ischemic Stroke
    Aug 9, 2007 · NXY-059 is ineffective for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms.
  69. [69]
    Guidelines for Adult Stroke Rehabilitation and Recovery
    The aim of this guideline is to provide a synopsis of best clinical practices in the rehabilitative care of adults recovering from stroke.
  70. [70]
    Rehabilitation and Recovery following Stroke
    1. Initial Stroke Rehabilitation Assessment · Recommendations · 2. Stroke Rehabilitation Unit Care · 2.1 Stroke Rehabilitation Unit Care · 3. Delivery of ...
  71. [71]
    Stroke rehabilitation: What to expect as you recover - Mayo Clinic
    Stroke rehabilitation is important for recovery after stroke. Learn about the physical, cognitive and other therapies used in stroke rehabilitation.
  72. [72]
    Effects of Constraint-Induced Movement Therapy on Patients With ...
    The results indicate that CI therapy is a powerful treatment for improving the rehabilitation of movement of the affected upper extremity in chronic stroke ...
  73. [73]
    The Preventive Effect of Dysphagia Screening on Pneumonia ... - NIH
    Dec 20, 2021 · In our meta-analysis, we found that dysphagia screening can prevent the development of pneumonia in patients with acute stroke. Various tools ...
  74. [74]
    Poststroke Depression: A Scientific Statement for Healthcare ...
    Dec 8, 2016 · Depression is common after stroke, affecting approximately one third of stroke survivors at any one time after stroke (compared with 5%–13% of ...
  75. [75]
    Improving post-stroke recovery: the role of the multidisciplinary ...
    Multidisciplinary team working is regarded as fundamental to delivering effective care across the stroke pathway. This paper discusses the contribution of team ...
  76. [76]
    Driving After Stroke
    Mar 18, 2024 · Ask for the office of driver safety to find out the vehicle or training requirements for people who've had a stroke.Missing: criteria | Show results with:criteria
  77. [77]
    Telerehabilitation: Has Its Time Come? | Stroke
    With widespread adoption of telerehabilitation catalyzed by the COVID-19 pandemic, there is great potential for improve care equity, addressing geographic, ...
  78. [78]
    Allogeneic Stem Cell Therapy for Acute Ischemic Stroke
    Jan 16, 2024 · This randomized clinical trial examines the efficacy and safety of MultiStem allogeneic stem cell therapy for acute ischemic stroke.
  79. [79]
    Prognostic Models of Mortality Following First‐Ever Acute Ischemic ...
    Feb 13, 2025 · Studies show that the highest mortality risk following a stroke occurs within the first 30 days, with an average annual mortality rate of about ...
  80. [80]
    Predictors of 30‐day mortality following the first episode of stroke ...
    Jun 25, 2024 · The study showed a high incidence of mortality within 30 days after the first stroke episode, with the highest proportion dying within 7 days of being ...Missing: mRS | Show results with:mRS
  81. [81]
    Long-Term Survival, Stroke Recurrence, and Life Expectancy After ...
    Apr 14, 2022 · The overall survival probability was 79.4% at 3 months, 73.0% at 1 year, 52.8% at 5 years, and 36.4% at 10 years. Cumulative incidence of stroke ...
  82. [82]
    Clinical Prediction of Functional Outcome After Ischemic Stroke
    Outcome at 3 months was a significant predictor of long-term mortality and functional outcome. ... Poststroke functional status (mRS at discharge or 30 days), ...
  83. [83]
    Hemorrhagic Transformation After Ischemic Stroke - PubMed Central
    Symptomatic hemorrhagic transformation (HT) is one of the complications most likely to lead to death in patients with acute ischemic stroke.Missing: dementia depression
  84. [84]
    Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae ...
    Apr 14, 2022 · The risks of dementia, depression, seizures, and fatigue all rise after stroke ... dementia among survivors of ischemic or hemorrhagic stroke ...Missing: prophylaxis | Show results with:prophylaxis
  85. [85]
    A systematic review and meta-analysis - PubMed
    Sep 22, 2025 · Background: Post-stroke epilepsy (PSE) is a complication of stroke and accounts for a large proportion of seizures in the elderly population.
  86. [86]
    Predictors of Poor Outcome in Patients with Acute Cerebral Infarction
    Many factors are associated with the poor outcome of patients with acute CI, including gender, age, congestive heart failure, dementia, stroke severity, and ...
  87. [87]
    Black Americans have worse stroke outcome compared with ... - NIH
    Aug 26, 2023 · In this prospective, population-based community sample, BAs had worse neurologic, functional and cognitive outcomes at 90 days compared to NHWs.
  88. [88]
    Racial and ethnic disparities in stroke outcomes: a scoping review of ...
    Although a majority of studies have discovered disparities in stroke recovery outcomes among racial/ethnic minorities, inconsistencies in the findings exist.
  89. [89]
    Impact of COVID-19 Infection on the Outcome of Patients With ...
    Patients with ischemic stroke and COVID-19 infection have more severe strokes and a higher mortality than patients with stroke without COVID-19 infection.
  90. [90]
    COVID-19 Pandemic and Quality of Care and Outcomes of Acute ...
    Aug 19, 2021 · Stroke severity was higher during COVID-19 than during pre–COVID-19 for both hemorrhagic stroke and ischemic stroke, and in-hospital death ...Missing: SF- tPA
  91. [91]
    Individuals with stroke three months after hospital discharge ...
    The results showed that the participants, who were evaluated during the COVID-19 pandemic reported worse generic and specific QOL related to the SF-36 and SSQOL ...Missing: tPA mRS<|control11|><|separator|>
  92. [92]
    Stroke: Strategies for Primary Prevention - AAFP
    Dec 15, 2003 · Because the excess stroke risk disappears within five years of smoking cessation, it is important to emphasize that it is never too late to quit ...
  93. [93]
    2024 Guideline for the Primary Prevention of Stroke
    Oct 21, 2024 · The 2024 primary prevention of stroke guideline provides recommendations based on current evidence for strategies to prevent stroke throughout the life span.
  94. [94]
    Effect of Standard vs Intensive Blood Pressure Control on the Risk of ...
    Jul 29, 2019 · Meaning Intensive blood pressure control to less than 130/80 mm Hg is recommended for secondary stroke prevention.
  95. [95]
    9. Management of Extracranial Carotid Disease and Intracranial ...
    In men with 50-69 percent stenosis the benefit of CEA is greatest when performed within 14 days of the qualifying event [Evidence Level A] and is attenuated ...
  96. [96]
    Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke
    Jan 21, 2020 · Specific agents recommended include clopidogrel 75 mg daily, aspirin/ER-DP 25 mg/200 mg twice daily, aspirin 75 mg to 100 mg daily, and ...
  97. [97]
    Apixaban versus Warfarin in Patients with Atrial Fibrillation
    Aug 30, 2011 · In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower ...Missing: DOACs | Show results with:DOACs
  98. [98]
    A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
    Nov 18, 2019 · Patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those who had a ...
  99. [99]
    Influenza vaccine effect on risk of stroke occurrence - Frontiers
    Jan 9, 2024 · The current meta-analysis further supports prior findings that influenza vaccination reduces stroke risk, particularly in patients with comorbidities.
  100. [100]
    Reducing Sodium Intake to Prevent Stroke
    Lowering sodium intake by 4% per year for 10 years is estimated to prevent between 30 000 and 83 000 deaths from stroke. Furthermore, there is no credible ...
  101. [101]
    AHA/ASA Stroke Secondary Prevention Guideline: Key Points
    Jun 2, 2021 · In selected patients, a glucagon-like protein 1 agonist or sodium glucose co-transporter 2 (SGLT2) inhibitor can be added to metformin.
  102. [102]
    Efficacy and safety of PCSK9 inhibitors for stroke prevention - PubMed
    PCSK9i reduced the LDL-C levels by 11 % and LpA levels by 8 %. PCSK9i were associated with a significant reduction in stroke risk (RR 0.75, 95 % CI 0.66-0.86, I ...Missing: refractory | Show results with:refractory